Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80187 refers to a laboratory test specifically designed to monitor therapeutic drug levels of posaconazole, an antifungal medication. Posaconazole is utilized primarily in the prevention and treatment of refractory invasive fungal infections, particularly in patients who have compromised immune systems, such as those with hematological cancers or individuals who have undergone organ transplants. This medication is effective against various fungal pathogens, including species of Candida and Aspergillus, Cryptococcus neoformans, zygomycetes, and other filamentous fungi. Due to significant variability in bioavailability and potential drug interactions among different patients, therapeutic monitoring of posaconazole is essential. This monitoring ensures that each patient receives an adequate dosage of the drug to achieve therapeutic efficacy, thereby improving clinical outcomes and preventing the development of drug-resistant fungal strains. Additionally, it helps to mitigate the risk of toxicity associated with the medication. The therapeutic drug monitoring process typically employs high-performance liquid chromatography to analyze serum or plasma samples in hospitalized patients. For outpatient or home settings, a finger prick may be used to collect a blood sample, which is then processed using the dried blood spot technique before being sent to the laboratory for analysis.
© Copyright 2026 Coding Ahead. All rights reserved.
The laboratory test for posaconazole is indicated for the following conditions:
The procedure for therapeutic drug monitoring of posaconazole involves several key steps:
Post-procedure care involves monitoring the patient’s clinical response to posaconazole therapy based on the results of the drug level testing. Healthcare providers may adjust the dosage of posaconazole as needed to ensure therapeutic efficacy while minimizing the risk of toxicity. Patients may be advised to report any side effects or symptoms that could indicate adverse reactions to the medication. Regular follow-up appointments may be scheduled to continue monitoring drug levels and overall health status, particularly for those with ongoing risk factors for fungal infections.
| Short Descr | DRUG ASSAY POSACONAZOLE | Medium Descr | DRUG ASSAY POSACONAZOLE | Long Descr | Posaconazole | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | 95 | Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2020-01-01 | Added | Code added. |
Get instant expert-level medical coding assistance.